Evidence map›Paper›PMID 35509360›Full record

ArticleAvicenna journal of medical biotechnology

Monoclonal Antibody Against Sortilin Induces Apoptosis in Human Breast Cancer Cells.

Miganoosh Simonian, Mozhan Haji Ghaffari, Ali Salimi, Ebrahim Mirzadegan, Niloufar Sadeghi, Nasim Ebrahimnezhad, Ghazaleh Fazli, Ramina Fatemi, Ali-Ahmad Bayat, Saeideh Milani and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Miganoosh SimonianDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mozhan Haji GhaffariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Ali SalimiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Ebrahim MirzadeganNanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Niloufar SadeghiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Nasim EbrahimnezhadMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Ghazaleh FazliMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Ramina FatemiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Ali-Ahmad BayatMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Saeideh MilaniBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Babak NegahdariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hodjattallah RabbaniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Academic Center for Education, Culture and Research · IRTehran University of Medical Sciences · IRHigh Institute for Education and Research in Transfusion Medicine · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sortilin has an important role in various malignances and can be used as a promising target to eradicate cancer cells. Methods: In this study, the expression of sortilin in 4T1 and MDA-MB231 cell lines was evaluated by flow cytometry and immunocytochemistry. Apoptosis assay was also applied to evaluate apoptosis induction in 4T1 and MDA-MB231 cell lines. Results: Based on cell surface flow cytometry results, anti-sortilin (2D8-E3) mAb could recognize sortilin molecules in 79.2% and 90.3% of 4T1 and MDA-MB231 cell-lines, respectively. The immunocytochemistry staining results confirmed sortilin surface expression. Apoptosis assay indicated that anti-sortilin mAb could induce apoptosis in 4T1 and MDA-MB231 cell lines. Conclusion: Our study revealed the important role of surface sortilin in breast carcinoma cell survival and its possible application as a therapeutic agent in cancer targeted therapies.

Indexed as

Breast cancerFlow cytometryMonoclonal antibodySortilin

Identifiers

PMID35509360
PMCPMC9017463
OpenAlexW4226199482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.